Over the past decade, the development of ‘simple’ blood tests that enable cancer screening, diagnosis or monitoring and facilitate the design of personalized therapies without the need for invasive tumour biopsy sampling has been a core ambition in cancer research. Data emerging from ongoing biomarker development efforts indicate that multiple markers, used individually or as part of a multimodal panel, are required to enhance the sensitivity and specificity of assays for early stage cancer detection. The discovery of cancer-associated molecular alterations that are reflected in blood at multiple dimensions (genome, epigenome, transcriptome, proteome and metabolome) and integration of the resultant multi-omics data have the potential to uncover novel biomarkers as well as to further elucidate the underlying molecular pathways. Herein, we review key advances in multi-omics liquid biopsy approaches and introduce the ‘nano-omics’ paradigm: the development and utilization of nanotechnology tools for the enrichment and subsequent omics analysis of the blood-circulating cancerome.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ferlay, J. et al. Cancer statistics for the year 2020: an overview. Int. J. Cancer 149, 778–789 (2021).
Lo, Y. M. D. & Lam, W. K. J. Towards multi-cancer screening using liquid biopsies. Nat. Rev. Clin. Oncol. 17, 525–526 (2020).
Hristova, V. A. & Chan, D. W. Cancer biomarker discovery and translation: proteomics and beyond. Expert. Rev. Proteom. 16, 93–103 (2019).
Duffy, M. J. Serum tumor markers in breast cancer: are they of clinical value? Clin. Chem. 52, 345–351 (2006).
Keedy, V. L. et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29, 2121–2127 (2011).
Tarone, R. E., Chu, K. C. & Brawley, O. W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11, 167–170 (2000).
Zhang, Z. & Chan, D. W. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomark. Prev. 19, 2995 (2010).
Chen, X. et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat. Commun. 11, 3475 (2020).
Olivier, M., Asmis, R., Hawkins, G. A., Howard, T. D. & Cox, L. A. The need for multi-omics biomarker signatures in precision medicine. Int. J. Mol. Sci. 20, 4781 (2019).
Campos-Carrillo, A. et al. Circulating tumor DNA as an early cancer detection tool. Pharmacol. Ther. 207, 107458 (2020).
Cayer, D. M., Nazor, K. L. & Schork, N. J. Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine. Hum. Mol. Genet. 25, R182–R189 (2016).
Calsina, B. et al. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/ mTOR axis in metastatic pheochromocytoma/ paraganglioma. Theranostics 9, 4946–4958 (2019).
Wang, H. et al. Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes. Nat. Commun. 10, 3718 (2019).
Ankney, J. A., Xie, L., Wrobel, J. A., Wang, L. & Chen, X. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients. BMC Med. Genomics 12, 78 (2019).
Zhang, B. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382–387 (2014).
Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926–930 (2018).
Lennon, A. M. et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 369, eabb9601 (2020).
Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745–759 (2020).
NHS-Galleri Trial. https://www.nhs-galleri.org/about-the-trial (2021).
Hayes, D. F. et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12, 4218–4224 (2006).
Cohen, S. J. et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213–3221 (2008).
De Bono, J. S. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302–6309 (2008).
Cristofanilli, M. et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): international expert consensus paper. Crit. Rev. Oncol. Hematol. 134, 39–45 (2019).
Lim, S. et al. Liquid biopsy: one cell at a time. NPJ Precis. Oncol. 3, 23 (2019).
Dai, J. et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal. Transduct. Target. Ther. 5, 145 (2020).
Wang, J., Ma, P., Kim, D. H., Liu, B. F. & Demirci, U. Towards microfluidic-based exosome isolation and detection for tumor therapy. Nano Today 37, 101066 (2021).
Ko, J. et al. Single extracellular vesicle protein analysis using immuno-droplet digital polymerase chain reaction amplification. Adv. Biosyst. 4, 1900307 (2020).
Zhang, P. et al. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat. Biomed. Eng. 3, 438–451 (2019).
Chen, Y. et al. Exosome detection via the ultrafast-isolation system: EXODUS. Nat. Methods 18, 212–218 (2021).
Wu, X. et al. Exosome-templated nanoplasmonics for multiparametric molecular profiling. Sci. Adv. 6, eaba2556 (2020).
Kang, Y.-T. et al. Dual-isolation and profiling of circulating tumor cells and cancer exosomes from blood samples with melanoma using immunoaffinity-based microfluidic interfaces. Adv. Sci. 7, 2001581 (2020).
Lim, J., Choi, M., Lee, H. J., Han, J. Y. & Cho, Y. A novel multifunctional nanowire platform for highly efficient isolation and analysis of circulating tumor-specific markers. Front. Chem. 7, 664 (2019).
McLendon, R. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science 362, eaav1898 (2018).
Kahles, A. et al. Comprehensive analysis of alternative splicing across tumors from 8,705 Patients. Cancer Cell 34, 211–224.e6 (2018).
Peng, X. et al. Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers. Cell Rep. 23, 255–269.e4 (2018).
Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929–944 (2014).
Rodriguez, H., Zenklusen, J. C., Staudt, L. M., Doroshow, J. H. & Lowy, D. R. The next horizon in precision oncology: proteogenomics to inform cancer diagnosis and treatment. Cell 184, 1661–1670 (2021).
Tweedie, S. et al. Genenames.org: the HGNC and VGNC resources in 2021. Nucleic Acids Res. 49, D939–D946 (2021).
Wang, L. B. et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell 39, 509–528.e20 (2021).
Rudnick, P. A. et al. A description of the clinical proteomic tumor analysis consortium (CPTAC) common data analysis pipeline. J. Proteome Res. 15, 1023–1032 (2016).
Tariq, M. U. et al. Methods for proteogenomics data analysis, challenges, and scalability bottlenecks: a survey. IEEE Access. 9, 5497–5516 (2021).
Eicher, T. et al. Challenges in proteogenomics: a comparison of analysis methods with the case study of the DREAM proteogenomics sub-challenge. BMC Bioinforma. 20, 669 (2019).
Subramanian, I., Verma, S., Kumar, S., Jere, A. & Anamika, K. Multi-omics data integration, interpretation, and its application. Bioinform. Biol. Insights 14, 1177932219899051 (2020).
Goble, C. et al. FAIR computational workflows under a creative commons attribution 4.0 international (CC BY 4.0) license. Work. Data Intell. 2, 108–121 (2020).
Chambers, M. C. et al. An accessible proteogenomics informatics resource for cancer researchers. Cancer Res. 77, e43–e46 (2017).
Srivastava, A. et al. Semantic workflows for benchmark challenges: enhancing comparability, reusability and reproducibility. Pacific Symposium on Biocomputing vol. 24 208–219 (World Scientific Publishing Co. Pte Ltd, 2019).
Huang, S., Chaudhary, K. & Garmire, L. X. More is better: recent progress in multi-omics data integration methods. Front. Genet. 8, 84 (2017).
Manzoni, C. et al. Genome, transcriptome and proteome: The rise of omics data and their integration in biomedical sciences. Brief. Bioinform. 19, 286–302 (2018).
Bratulic, S., Gatto, F. & Nielsen, J. The translational status of cancer liquid biopsies. Regen. Eng. Transl. Med. 7, 312–352 (2021).
Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic — implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297–312 (2021).
Li, J. et al. The growing impact of micro/nanomaterial-based systems in precision oncology: translating “multiomics” technologies. Adv. Funct. Mater. 30, 1909306 (2020).
Martín-Gracia, B. et al. Nanoparticle-based biosensors for detection of extracellular vesicles in liquid biopsies. J. Mater. Chem. B 8, 6710 (2020).
Viswambari Devi, R., Doble, M. & Verma, R. S. Nanomaterials for early detection of cancer biomarker with special emphasis on gold nanoparticles in immunoassays/sensors. Biosens. Bioelectron. 68, 688–698 (2015).
Moro, L., Turemis, M., Marini, B., Ippodrino, R. & Giardi, M. T. Better together: strategies based on magnetic particles and quantum dots for improved biosensing. Biotechnol. Adv. 35, 51–63 (2017).
Kelley, S. O. et al. Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. Nat. Nanotechnol. 9, 969–980 (2014).
Yaari, Z. et al. A perception-based nanosensor platform to detect cancer biomarkers. Sci. Adv. 7, eabj0852 (2021).
Kim, M. et al. Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning. Nat. Biomed. Eng. 6, 267–275 (2022).
Hanash, S. M., Pitteri, S. J. & Faca, V. M. Mining the plasma proteome for cancer biomarkers. Nature 452, 571–579 (2008).
Paul, J. & Veenstra, T. D. Separation of serum and plasma proteins for in-depth proteomic analysis. Separations 9, 89 (2022).
Liotta, L. A., Ferrari, M. & Petricoin, E. Written in blood. Nature 425, 905 (2003).
Fredolini, C. et al. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J. 12, 504–518 (2010).
Longo, C. et al. Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 4, e4763 (2009).
Tamburro, D. et al. Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J. Am. Chem. Soc. 133, 19178–19188 (2011).
Cedervall, T. et al. Understanding the nanoparticle-protein corona using methods to quntify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104, 2050–2055 (2007).
Hadjidemetriou, M. & Kostarelos, K. Nanomedicine: evolution of the nanoparticle corona. Nat. Nanotechnol. 12, 288–290 (2017).
García-Álvarez, R., Hadjidemetriou, M., Sánchez-Iglesias, A., Liz-Marzán, L. M. & Kostarelos, K. In vivo formation of protein corona on gold nanoparticles. the effect of their size and shape. Nanoscale 10, 1256–1264 (2018).
Hadjidemetriou, M. et al. In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles. ACS Nano 9, 8142–8156 (2015).
Kamaly, N., Farokhzad, O. C. & Corbo, C. Nanoparticle protein corona evolution: from biological impact to biomarker discovery. Nanoscale 14, 1606–1620 (2022).
Hadjidemetriou, M. et al. The human in vivo biomolecule corona onto pegylated liposomes: a proof-of-concept clinical study. Adv. Mater. 31, e1803335 (2019).
Hadjidemetriou, M., Al-ahmady, Z., Buggio, M., Swift, J. & Kostarelos, K. A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona. Biomaterials 188, 118–129 (2019).
Kostarlos, K. & Hadjidemetriou, M. Detection of cancer biomarkers using nanoparticles. Patent WO2018046542A1 (2018).
Hadjidemetriou, M. et al. Nano-scavengers for blood biomarker discovery in ovarian carcinoma. Nano Today 34, 100901 (2020).
Di Domenico, M. et al. Nanoparticle-biomolecular corona: a new approach for the early detection of non-small-cell lung cancer. J. Cell. Physiol. 234, 9378–9386 (2019).
Digiacomo, L. et al. A proteomic study on the personalized protein corona of liposomes. Relevance for early diagnosis of pancreatic DUCTAL adenocarcinoma and biomarker detection. J. Nanotheranostics 2, 82–93 (2021).
Blume, J. E. et al. Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nat. Commun. 11, 3662 (2020).
Chantada-Vázquez, M. D. P. et al. Protein corona gold nanoparticles fingerprinting reveals a profile of blood coagulation proteins in the serum of her2-overexpressing breast cancer patients. Int. J. Mol. Sci. 21, 8449 (2020).
Gómez, B. B. et al. Detection of circulating serum protein biomarkers of non-muscle invasive bladder cancer after protein corona-silver nanoparticles analysis by swath-ms. Nanomaterials 11, 2384 (2021).
Gardner, L. et al. The biomolecule corona of lipid nanoparticles contains circulating cell-free DNA. Nanoscale Horiz. 5, 1476–1486 (2020).
Lee, H. J. et al. Magnetic nanowire networks for dual-isolation and detection of tumor-associated circulating biomarkers. Theranostics 8, 505–517 (2018).
Gwak, H. et al. On-chip isolation and enrichment of circulating cell-free DNA using microfluidic device. Biomicrofluidics 13, 24113 (2019).
Jeon, S. H. et al. Efficient capture and isolation of tumor-related circulating cell-free dna from cancer patients using electroactive conducting polymer nanowire platforms. Theranostics 6, 828–836 (2016).
Sina, A. A. I. et al. Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nat. Commun. 9, 4915 (2018).
Zhou, X. et al. Leukocyte-repelling biomimetic immunomagnetic nanoplatform for high-performance circulating tumor cells isolation. Small 15, 1900558 (2019).
Hong, W., Lee, S., Chang, H. J., Lee, E. S. & Cho, Y. Multifunctional magnetic nanowires: a novel breakthrough for ultrasensitive detection and isolation of rare cancer cells from non-metastatic early breast cancer patients using small volumes of blood. Biomaterials 106, 78–86 (2016).
Poudineh, M. et al. Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking. Nat. Nanotechnol. 12, 274–281 (2017).
Mohamadi, R. M. et al. Nanoparticle-mediated binning and profiling of heterogeneous circulating tumor cell subpopulations. Angew. Chem. Int. Ed. 54, 139–143 (2015).
Zhou, X. et al. Multifunctional luminescent immuno-magnetic nanoparticles: toward fast, efficient, cell-friendly capture and recovery of circulating tumor cells. J. Mater. Chem. B 7, 393–400 (2019).
Lim, J. et al. Direct isolation and characterization of circulating exosomes from biological samples using magnetic nanowires. J. Nanobiotechnol. 17, 1 (2019).
Park, M. H. et al. Enhanced isolation and release of circulating tumor cells using nanoparticle binding and ligand exchange in a microfluidic chip. J. Am. Chem. Soc. 139, 2741–2749 (2017).
Ke, Z. et al. Programming thermoresponsiveness of nanovelcro substrates enables effective purification of circulating tumor cells in lung cancer patients. ACS Nano 9, 62–70 (2015).
Wang, S. et al. Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew. Chem. Int. Ed. 50, 3084–3088 (2011).
Dong, J. et al. Bio-inspired NanoVilli chips for enhanced capture of tumor-derived extracellular vesicles: toward non-invasive detection of gene alterations in non-small cell lung cancer. ACS Appl. Mater. Interfaces 11, 13973–13983 (2019).
Sun, N. et al. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat. Commun. 11, 4489 (2020).
Zhang, N. et al. Electrospun TiO2 nanofiber-based cell capture assay for detecting circulating tumor cells from colorectal and gastric cancer patients. Adv. Mater. 24, 2756–2760 (2012).
Yoon, H. J. et al. Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat. Nanotechnol. 8, 735–741 (2013).
Loeian, M. S. et al. Liquid biopsy using the nanotube-CTC-chip: capture of invasive CTCs with high purity using preferential adherence in breast cancer patients. Lab. Chip 19, 1899–1915 (2019).
Zhang, P., He, M. & Zeng, Y. Ultrasensitive microfluidic analysis of circulating exosomes using a nanostructured graphene oxide/polydopamine coating. Lab. Chip 16, 3033–3042 (2016).
Schweiger, M. R., Kerick, M., Timmermann, B. & Isau, M. The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. Cancer Metastasis Rev. 30, 199–210 (2011).
Papafilippou, L., Claxton, A., Dark, P., Kostarelos, K. & Hadjidemetriou, M. Protein corona fingerprinting to differentiate sepsis from non-infectious systemic inflammation. Nanoscale 12, 10240–10253 (2020).
Chetwynd, A. J. & Lynch, I. The rise of the nanomaterial metabolite corona, and emergence of the complete corona. Environ. Sci. Nano 7, 1041–1060 (2020).
Chetwynd, A. J., Zhang, W., Thorn, J. A., Lynch, I. & Ramautar, R. The nanomaterial metabolite corona determined using a quantitative metabolomics approach: a pilot study. Small 16, 2000295 (2020).
Raesch, S. S. et al. Proteomic and lipidomic analysis of nanoparticle corona upon contact with lung surfactant reveals differences in protein, but not lipid composition. ACS Nano 9, 11872–11885 (2015).
Kapralov, A. A. et al. Adsorption of surfactant lipids by single-walled carbon nanotubes in mouse lung upon pharyngeal aspiration. ACS Nano 6, 4147–4156 (2012).
Martel, J. et al. Fatty acids and small organic compounds bind to mineralo-organic nanoparticles derived from human body fluids as revealed by metabolomic analysis. Nanoscale 8, 5537–5545 (2016).
Pink, M., Verma, N., Kersch, C. & Schmitz-Spanke, S. Identification and characterization of small organic compounds within the corona formed around engineered nanoparticles. Environ. Sci. Nano 5, 1420 (2018).
Grintzalis, K., Lawson, T. N., Nasser, F., Lynch, I. & Viant, M. R. Metabolomic method to detect a metabolite corona on amino-functionalized polystyrene nanoparticles. Nanotoxicology 13, 783–794 (2019).
La Barbera, G. et al. A comprehensive analysis of liposomal biomolecular corona upon human plasma incubation: the evolution towards the lipid corona. Talanta 209, 120487 (2020).
Hellstrand, E. et al. Complete high-density lipoproteins in nanoparticle corona. FEBS J. 276, 3372–3381 (2009).
Lee, J. Y. et al. Analysis of lipid adsorption on nanoparticles by nanoflow liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 410, 6155–6164 (2018).
Hadjidemetriou, M. et al. Nanoparticle-enabled enrichment of longitudinal blood proteomic fingerprints in Alzheimer’s disease. ACS Nano 15, 7357–7369 (2021).
Lyons, N. et al. Early Detection and Diagnosis of Cancer: A roadmap to the future. Cancer Research UK https://www.cancerresearchuk.org/funding-for-researchers/research-opportunities-in-early-detection-and-diagnosis/early-detection-and-diagnosis-roadmap (2021).
Hou, S. et al. Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew. Chem. Int. Ed. 52, 3379–3383 (2013).
Shen, M. Y. et al. Glycan stimulation enables purification of prostate cancer circulating tumor cells on PEDOT NanoVelcro chips for RNA biomarker detection. Adv. Healthc. Mater. https://doi.org/10.1002/adhm.201700701 (2018).
The authors acknowledge funding support from the NIHR Manchester Biomedical Research Centre (BRC) and the Cancer Research UK International Alliance for Cancer Early Detection (ACED; EICEDAAP\100013).
The authors declare no competing interests.
Peer review information
Nature Reviews Clinical Oncology thanks D. Heller, J.X.J. Zhang and the other, anonymous, reviewers for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gardner, L., Kostarelos, K., Mallick, P. et al. Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome. Nat Rev Clin Oncol 19, 551–561 (2022). https://doi.org/10.1038/s41571-022-00645-x